CoChat

Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms

Open access
Corbin, Karen D, Driscoll, Kimberly A, Pratley, Richard E, Smith, Steven R, Maahs, David M, Mayer-Davis, Elizabeth J, Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) · 2018 · Endocrine Reviews

The DOI matches its Crossref record; 475 of the 479 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

There has been an alarming increase in the prevalence of obesity in people with type 1 diabetes in recent years. Although obesity has long been recognized as a major risk factor for the development of type 2 diabetes and a catalyst for complications, much less is known about the role of obesity in the initiation and pathogenesis of type 1 diabetes. Emerging evidence suggests that obesity contributes to insulin resistance, dyslipidemia, and cardiometabolic complications in type 1 diabetes. Unique therapeutic strategies may be required to address these comorbidities within the context of intensive insulin therapy, which promotes weight gain. There is an urgent need for clinical guidelines for the prevention and management of obesity in type 1 diabetes. The development of these recommendations will require a transdisciplinary research strategy addressing metabolism, molecular mechanisms, lifestyle, neuropsychology, and novel therapeutics. In this review, the prevalence, clinical impact, energy balance physiology, and potential mechanisms of obesity in type 1 diabetes are described, with a special focus on the substantial gaps in knowledge in this field. Our goal is to provide a framework for the evidence base needed to develop type 1 diabetes-specific weight management recommendations that account for the competing outcomes of glycemic control and weight management.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2017-00191

Cites

475 of 476 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Items 201–400 of 476

Cited by

See all 273

Metadata

Authors
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON)
Affiliations
  • Translational Research Institute for Metabolism and Diabetes (US)
  • University of Colorado Denver (US)
  • Stanford Medicine (US)
  • Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Corresponding author
Corbin, Karen D
Venue
Endocrine Reviews
Published
2018-07-27
Volume
39
Issue
5
Pages
629-663
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2884950815
Cited by
262
References
479
Citations by year
2026: 28 · 2025: 35 · 2024: 40 · 2023: 33 · 2022: 43 · 2021: 41 · 2020: 23 · 2019: 14 · 2018: 5
FWCI
3.19
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • North Carolina State University
  • Bigfoot Biomedical
  • Insulet Corporation
  • Orexigen Therapeutics
  • Five Prime Therapeutics
  • Dexcom
  • Zafgen
  • NGM Biopharmaceuticals
  • York University
  • Eisai
  • Novo Nordisk
  • University of North Carolina at Chapel Hill
  • University of Colorado Denver
  • Abbott Diabetes Care
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, type 1 diabetes, insulin resistance, dyslipidemia, cardiometabolic complications, intensive insulin therapy, weight gain, energy balance, obesity pathogenesis, weight management, glycemic control, obesity prevalence
MeSH terms
Diabetes Mellitus, Type 1, Humans, Insulin Resistance, Life Style, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.